Dossier assessment
Olaparib (ovarian cancer; first-line maintenance in combination with bevacizumab) - Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Olaparib (ovarian cancer; first-line maintenance in combination with bevacizumab) - Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Olaparib (ovarian cancer; first-line maintenance in combination with bevacizumab) - Benefit assessment according to §35a Social Code Book V
Dossier assessment
Adult patients with advanced (FIGO stages III and V) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status.
Patients without detectable tumour after primary surgery and patients without detectable tumour/with complete response following chemotherapy: indication of considerable added benefit.
Patients without detectable tumour after interval surgery and patients with partial response: indication of lesser benefit.
Additional information
Federal Joint Committee (G-BA)
2021.06.04 A G-BA decision was published.
Project details
- Project no.
- A20-111
- Commission
- Commission awarded on 02.12.2020 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
Connected Projects
-
Dossier assessment
Olaparib (ovarian cancer) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Olaparib (breast cancer) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Olaparib (ovarian, fallopian tube, peritoneal cancer) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Olaparib - Assessment according to §35a (para. 1., sentence 10) Social Code Book V (dossier assessment)
Status: Commission completed
-
Dossier assessment
Olaparib (adenocarcinoma of the pancreas) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Olaparib (prostate cancer) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Addendum
Olaparib (ovarian cancer; first-line maintenance in combination with bevacizumab) - Addendum to Commission A20-111
Status: Commission completed
-
Dossier assessment
Olaparib (ovarian cancer) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Olaparib (prostate cancer) - Benefit assessment according to § 35a SGB V
Status: Commission completed
-
Dossier assessment
Olaparib (maintenance in combination with durvalumab; endometrial cancer) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Olaparib (ovarian cancer) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Olaparib (breast cancer, adjuvant) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed